The effect of hemodialysis on cycloserine, ethionamide, para- aminosalicylate, and clofazimine

Chest

Volumn 116, Issue 4, 1999, Pages 984-990

  Malone, Rebecca S ^a   Fish, Douglas N ^b   Spiegel, David M ^b   Childs, James M ^a   Peloquin, Charles A ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cycloserine; Dofazimine; Ethionamide; Hemodialysis; Para aminosalicylate; Pharmacokinetics; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; COLORIMETRY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OUTPATIENT; PRIORITY JOURNAL; VENOUS BLOOD;

EID: 0032743079     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.4.984     Document Type: Article

References (34)

1. 1 Murthy BVR, Pereira JG. A 1990s perspective of hepatitis C, human immunodeficiency virus, and tuberculosis infections in dialysis patients. Semin Nephrol 1997; 17:346-363
2. 2 Lundin AP, Adler AJ, Berlyne GM, et al. Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 1979; 67:597-602
3. 3 Sasaki S, Akiba T, Suenaga M, et al. Ten year's survey of dialysis-associated tuberculosis. Nephron 1979; 24:141-145
4. 4 Andrew OT, Schoenfeld PY, Hopewell PC, et al. Tuberculosis in patients with end-stage renal disease. Am J Med 1980; 68:59-65
5. 5 Rutsky EA, Rostand SG. Mycobacteriosis in patients with chronic renal failure. Arch Intern Med 1980; 140:57-61
6. 6 Belcon MC, Smith EKM, Kahana LM, et al. Tuberculosis in dialysis patients. Clin Nephrol 1982; 17:14-18
7. 7 Cuss FMC, Carmichael DJS. Linington A, et al. Tuberculosis in renal failure: a high incidence in patients born in the third world. Clin Nephrol 1986; 25:129-133
8. 8 Ozdemir FN, Guz G, Kayatas M, et al. Tuberculosis remains an important factor in the morbidity and mortality of hemodialysis patients. Transplant Proc 1998; 30:846-847
9. 9 Tokars JI, Miller ER, Alter MJ, et al. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO J 1998; 44:98-107
10. 10 Cengiz K. Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron 1996; 73:421-424
11. 11 Mitwalli A. Tuberculosis in patients on maintenance dialysis. Am J Kidney Diseases 1991; 18:579-582
12. 12 Papadimitriou M, Memmos D, Metaxaz P. Tuberculosis in patients on regular hemodialysis. Nephron 1979; 24:53-57
13. 13 Bobrowitz ID. Active tuberculosis undiagnosed until autopsy. Am J Med 1982; 72:650-8
14. 14 McWhinney N, Khan O, Williams G. Tuberculosis in patients undergoing maintenance hemodialysis and renal transplantation. Br J Surg 1981; 68:408-411
15. 15 Al-Homrany M. Successful therapy of tuberculosis in hemodialysis patients. Am J Nephrol 1997; 17:32-35
16. 16 Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance 1994-1997. N Engl J Med 1994; 338:1641-1649
17. 17 Iseman MD. Treatment of multi-drug resistant tuberculosis. N Engl J Med 1993; 329:784-791
18. 18 American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149:1359-1374
19. 19 Lee CS, Marbury TC, Benet LZ. Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol. J Pharmacokinet Biopharm 1980; 8:69-81
20. 20 Gibson TP. Problems in designing hemodialysis drug studies. Pharmacotherapy 1985; 5:23-29
21. 21 Barbhaiya RH, Knupp CA, Forgue ST, et al. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther 1990; 48:268-276
22. 22 Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997; 18:79-87
23. 23 Zitkova L, Tousek J. Pharmacokinetics of cycloserine and terizidone. Chemotherapy 1974; 20:18-28
24. 24 Peloquin CA, James GT, McCarthy E, et al. Pharmacokinetic evaluation of ethionamide suppositories. Pharmacotherapy 1991; 11:359-363
25. 25 Peloquin CA, Henshaw TL, Huitt GA, et al. Pharmacokinetic evaluation of para-aminosalicylic acid grannules. Pharmacotherapy 1994; 14:40-46
26. 26 Garrelts JC. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. DICP Ann Pharmacother 1991; 25:525-531
27. 27 Matzke GR, Millikin SP. Influence of renal function and dialysis on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ. eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics, 1992; 8·1-8·49
28. 28 Peloquin CA. Antituberculosis drugs: pharmacokinetics. In: Heifets LB, ed. Drug susceptibilities in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991; 59-88
29. 29 Jacobus Pharmaceutical Company. Prescribing information for PASER® granules. Princeton, NJ: Jacobus Pharmaceutical Company, 1996
30. 30 Shuler C, Golper TA, Bennet WM. Prescribing drugs in renal disease. In: Brenner BM, ed. Brenner and Rector's the kidney. 5th ed. Philadelphia, PA: WB Saunders, 1996:2653-2702
31. 31 McEvoy GK. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists. 1998:444-446
32. 32 Ogg CS, Toseland PA, Cameron JS. Pulmonany tuberculosis in patient on intermittent hemodialysis. BMJ 1968; 2:283-284
33. 33 Smith FW, Catto GRD, MacLeod M. Treatment of pulmonary tuberculosis in a patient on maintenance hemodialysis. Postgrad Med J 1974; 50:478-481
34. 34 Peloquin CA, Berning SE, Huitt GA, et al. Once-daily and twice-daily dosing of p-aminosalicylic acid (PAS) granules. Am J Respir Crit Care Med 1999; 159:932-934